Esperion (ESPR) announced the presentation of two post-hoc analyses from the CLEAR Outcomes trial focused on the risk of ischemic stroke and major adverse cardiovascular events, or MACE, in patients with autoimmune or inflammatory diseases at the American College of Cardiology’s Annual Scientific Session. The company said the analysis demonstrated a 22% reduced risk of ischemic stroke for patients taking bempedoic acid compared to placebo. A separate analysis showed bempedoic acid reduced MACE in high-risk patients with autoimmune or inflammatory diseases similarly to those without.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion management to meet with Piper Sandler
- Esperion says bempedoic acid receives recommendations in ACC/AHA Guideline
- Esperion price target raised to $5 from $4 at Citizens
- Esperion Therapeutics Flags Material Weakness in Financial Controls, Raising Reporting and Regulatory Risks
- Esperion Therapeutics: Strong 2025 Execution, Expanding Cardiometabolic Platform, and Vision 2040 Underpin Buy Rating